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Abstract Dehydroascorbic acid (DHA) is abundant in the hu-
man diet and also is generated from vitamin C (ascorbic acid,
AA) in the lumen of the gastrointestinal tract. DHA is absorbed
from the lumen of the small intestine and reduced to AA, which
subsequently circulates in the blood. Utilization of AA as an
antioxidant and enzyme cofactor causes its oxidation to DHA
in extracellular £uid and cells. DHA has an important role in
many cell types because it can be used to regenerate AA. Both
physiological (e.g. insulin, insulin-like growth factor I, cyclic
AMP) and pathological (e.g. oxidative stress, diabetes, sepsis)
factors alter the transport and metabolic mechanisms responsi-
ble for this DHA recycling. ) 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Vitamin C (ascorbic acid, AA) acts as a cofactor in the
enzymatic biosynthesis of collagen, carnitine, and catechol-
amine and peptide neurohormones. AA also prevents injuri-
ous e¡ects of oxidants because it reduces reactive oxygen and
nitrogen species to stable molecules. Decreased serum vitamin
C concentration in humans is associated with neurologic
problems and eventually causes scurvy [1]. As AA loses elec-
trons in biosynthetic or antioxidant reactions, it becomes oxi-
dized to the short-lived ascorbyl radical and then to dehy-
droascorbic acid (DHA). For instance, AA donates reducing
equivalents to reactive metabolites of dietary £avonoids (e.g.
semiquinone or phenoxy radicals of quercetin), thereby spar-
ing other cellular components from oxidation but incidentally
producing DHA [2]. DHA and AA have distinct e¡ects on cell
function, as becomes obvious under conditions characterized
by oxidative stress (Table 1).
Vitamin C is synthesized de novo from glucose in the livers
of most adult mammals except guinea pigs, primates and hu-
mans, which depend on dietary sources. Ingesting either AA
or DHA raises the serum AA concentration to similar extents
in normal human subjects [3,4]. Thus DHA can serve as a
dietary source of vitamin C for humans, although it is a
poor source for some animals (e.g. Osteogenic Disorder Shio-
nogi rat [5]). Evidently cellular mechanisms of transport and
metabolism convert DHA to AA. These mechanisms are im-
portant because the human diet normally contains DHA as
well as AA [6]. Indeed, the commercial and domestic process-
ing of foods oxidizes AA to DHA. There exists a widely held
understanding that dietary AA and DHA possess roughly
equivalent bioavailability in humans. It is because both mol-
ecules are commonly thought to be bioavailable that the vi-
tamin C content of foods is usually reported as total vitamin
C, i.e. the sum of AA and DHA contents. The purpose of this
review is to describe the mechanisms by which DHA increases
the concentration of AA in cells and extracellular £uid and to
discuss their relevance to disease.
2. Transport of AA and DHA
The gastrointestinal tract is the principal site of absorption
for AA and DHA. In addition to the amounts ingested, DHA
is produced when AA reacts with oxidants in the lumen of the
gastrointestinal tract [7]. For instance, oxidation of AA by
quercetin metabolites [2] may contribute to the decrease in
AA bioavailability caused by quercetin administration in
rats [8]. DHA itself is degraded to diketogulonic acid by bi-
carbonate at alkaline pH in vitro [9]. However, it is unlikely
that DHA is exposed to these destabilizing conditions in vivo,
because the alkaline secretions from the pancreas and duode-
nal glands mix with the strongly acidic gastric juice to form a
slightly acidic £uid in the lumen of the small intestine.
Both DHA and AA are absorbed from the lumen of the
human intestine by enterocytes, as has been shown by mea-
suring transport activities in luminal (brush border) mem-
brane vesicles [10]. The absorption sites are found along the
entire length of the small intestine. In vesicles prepared from
the jejunum, Naþ^ascorbate cotransporters take up the ion-
ized form of AA with high a⁄nity (Km = 0.2 mM) while a
Naþ-independent process of facilitated di¡usion takes up
DHA with lower a⁄nity (Km =0.8 mM). However, the max-
imal rates of uptake for AA and DHA are similar. Further-
more, glucose inhibits AA but not DHA uptake, which may
increase the relative bioavailability of the oxidized form of
vitamin C [10].
Human enterocytes contain DHA reductases that convert
DHA to AA [11]. These enzymes keep the intracellular con-
centration of DHA low and thereby maintain a gradient fa-
voring continued uptake of oxidized vitamin C across the
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enterocytes’ luminal membrane. Any DHA that escapes re-
duction in enterocytes and enters the blood may be taken
up and reduced to AA by other cell types. If the DHA con-
centration in blood rises nonetheless, then it is ¢ltered from
the plasma at the renal corpuscles and reabsorbed across the
luminal membranes of the renal tubules for subsequent reduc-
tion [12].
It is not known how AA is transported out of epithelial
cells to the blood during intestinal absorption and renal tub-
ular reabsorption of vitamin C. One possibility is that ionized
AA (ascorbate) di¡uses from the cytosol to the extracellular
£uid through volume-sensitive anion channels in the basolat-
eral membrane and then enters the blood plasma through
discontinuities in the capillary wall. There are two lines of
evidence in support of this hypothetical mechanism. First,
epithelial cells swell markedly during transepithelial transport
of nutrients; for example, sodium-dependent absorption of
glucose or alanine causes a sustained increase in cell volume
in enterocytes and renal tubular cells [13^15]. Second, cell
swelling has been shown to transiently and reversibly stimu-
late ascorbate e¥ux through channels or pores in the plasma
membrane of astrocytes [16,17]. However, the molecular iden-
tities of the proteins mediating AA transport across the baso-
lateral membranes of intestinal and renal epithelia have yet to
be determined.
AA circulates in the blood, predominantly in the form of
the ascorbate anion. Many cell types are capable of high-af-
¢nity vitamin C uptake through Naþ^ascorbate cotransport-
ers, including vascular smooth muscle and endothelial cells,
bone osteoblasts and cerebral astrocytes [16^22]. Subsequent
utilization of vitamin C as either an enzyme cofactor or anti-
oxidant causes its oxidation. The DHA thus generated intra-
cellularly may exit cells through facilitative glucose transport-
ers.
Instead of allowing its immediate excretion from the body,
numerous cell types can clear DHA from the extracellular
£uid. Among those that take up DHA and reduce it to AA
are neutrophils, erythrocytes, smooth muscle cells, hepato-
cytes, astrocytes and osteoblasts [19^21,23^28]. DHA uptake
is not mediated by Naþ^ascorbate cotransporters because it is
neither dependent on Naþ nor blocked by an antagonist of
Naþ^ascorbate cotransport (4,4P-diisothiocyanatostilbene-
2,2P-disulfonic acid) [23]. Many cells possess both Naþ^ascor-
bate cotransporters and the ability to take up and reduce
DHA. In contrast, human neutrophils lack Naþ^ascorbate
cotransporters but incubation of these myeloid cells with
DHA in vitro increases their intracellular AA concentration
levels to those found in mature neutrophils in vivo [26].
In bone, the oxidation and regeneration of AA may be an
important way for the osteoid-resorbing activity of osteoclasts
to stimulate the osteoid-forming activity of osteoblasts [20].
Resorbing osteoclasts are sources of reactive oxygen species
that oxidize extracellular AA. As DHA is produced in the
extracellular £uid, it may be taken up and reduced to AA
by neighboring osteoblasts. The rate of rise in intracellular
AA concentration is much faster when osteoblasts are incu-
bated with DHA than with AA [20]. Intracellular AA stimu-
lates the osteoblasts to produce collagenous osteoid that sub-
sequently becomes calci¢ed [29]. Thus DHA may couple bone
resorption and formation.
Glucose exerts an e¡ect on the initial rate of DHA uptake
that varies between cell types. Some are acutely inhibited
by physiological concentrations of glucose (osteoblasts,
smooth muscle cells), others are less sensitive (erythrocytes,
astrocytes), and DHA uptake across some cell membranes is
not detectably changed by glucose (luminal membranes of
intestinal enterocytes and renal tubular cells) [10,12,19^
21,23^25].
DHA competes with glucose for uptake through several
isoforms of the facilitative glucose transporters (e.g.
GLUT1, GLUT3 and GLUT4) [19^21,23^26,30]. Agents
that enhance the activity of these facilitative glucose trans-
porters also increase the initial rate of DHA uptake, such as
colony-stimulating factors in neutrophils [26], insulin and in-
sulin-like growth factor I in osteoblasts [20], and cyclic AMP
in astrocytes [21]. It is clear that Naþ^ascorbate cotransport-
ers and facilitative glucose transporters can be regulated inde-
pendently. For instance, colony-stimulating factors enhance
DHA uptake in human neutrophils that lack Naþ^ascorbate
cotransporters [26]. Bone-derived osteoblasts provide another
intriguing example. In osteoblasts, transforming growth fac-
tor-L increases the maximal rate of AA uptake through Naþ^
ascorbate cotransporters but does not stimulate DHA uptake
[22], while insulin increases the maximal rate of DHA uptake
through glucose transporters without changing Naþ^ascor-
bate cotransport activity [20].
Besides DHA permeation of facilitative glucose transport-
ers, additional DHA uptakes occur through a glucose-insen-
sitive mechanism in human erythrocytes [24] and rat astro-
cytes [23]. In primary cultures of rat astrocytes, for example,
uptake of DHA (5^200 WM) is inhibited only partially by a
relatively high concentration of glucose (10 mM) [23]. The
Table 1
The roles of DHA and AA in mammalian cells under conditions characterized by oxidative stress
DHA
Competitively inhibits facilitative glucose transporters, hexokinase, glyceraldehyde-3-phosphate dehydrogenase, glucose-6-phosphate dehydroge-
nase
Oxidizes NADPH and glutathione
Stimulates synthesis of NADPH and glutathione
Increases AA concentration in metabolically competent cells (e.g. astrocytes)
Kills susceptible cells (e.g. neurons)
AA
Increases synthesis of collagen, carnitine, catecholamine and peptide hormones
Terminates free radical chain reactions by scavenging reactive oxygen and nitrogen species
Prevents or reverses oxidation of glutathione and K-tocopherol
Donates electrons through membrane oxidoreductases to extracellular acceptors
Increases cell survival
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remaining, glucose-insensitive accumulation of intracellular
AA from DHA is blocked by phloretin and cytochalasin B,
like facilitated glucose transport, but also is inhibited revers-
ibly by sul¢npyrazone, unlike glucose transport.
The epithelial cells of the renal tubules reabsorb DHA after
it has been ¢ltered from the plasma at the renal corpuscles.
Studies of brush-border membrane vesicles prepared from rat
renal cortex, which are representative of the luminal mem-
branes of proximal tubule cells, have shown that AA uptake
occurs through Naþ^ascorbate cotransport while DHA up-
take occurs by a Naþ-independent process [12]. Since they
cannot be inhibited by glucose, it is evident that both AA
and DHA uptakes occur independently of glucose transport-
ers in these renal membranes [12].
3. Regeneration of AA from oxidized vitamin C
The dismutation of a pair of ascorbyl radicals, which is
catalyzed by NADH-dependent semidehydroascorbate reduc-
tase, produces one molecule of AA and one of DHA. DHA
can be converted to AA by NADPH-dependent thioredoxin
reductase or glutathione-dependent DHA reductase [31]. In
contrast to an unsubstantiated opinion published recently
[32], these reactions do not produce hydrogen peroxide or
other reactive oxygen species while regenerating AA.
The reduction of DHA to AA by intracellular enzymes
keeps the cytosolic concentration of DHA low and thus con-
tributes to a gradient favoring DHA uptake across the plasma
membrane. DHA may be reduced to AA as it permeates the
plasma membrane and at other intracellular locations [24].
Within a few minutes, DHA uptake and reduction can raise
the AA concentration in the cytosol of some cell types to
millimolar levels that are 10^100 times greater than the AA
concentration in extracellular £uids [19,23].
Reductants derived from cell metabolism convert intracel-
lular DHA to AA. The NADPH generated by the pentose
phosphate pathway of glucose metabolism is an example. It
is likely that redundant mechanisms involving NADPH, glu-
tathione, and perhaps other thiols ensure DHA reduction [21].
Reduction of large amounts of DHA to AA by NADPH-
and glutathione-dependent reactions may decrease the intra-
cellular concentrations of NADPH and glutathione markedly
[21,33,34]. DHA also inhibits the activities of puri¢ed hexoki-
nase, glyceraldehyde-3-phosphate dehydrogenase and glucose-
6-phosphate dehydrogenase, but this does not occur when
su⁄ciently high concentrations of the enzymes’ speci¢c sub-
strates are present [34]. Moreover, DHA indirectly stimulates
the pentose phosphate pathway to produce NADPH and sub-
sequently increases intracellular glutathione concentration
above basal levels [35]. These time-dependent e¡ects of
DHA are re£ected in its ability to modulate the resistance
of lymphocytes against killing by hydrogen peroxide [35].
Short- (20 min to 2 h) and long-term (24^48 h) DHA pretreat-
ment had opposing e¡ects on cell survival. Preincubation with
DHA for 20 min to 2 h enhanced hydrogen peroxide-induced
apoptosis. In contrast, pretreatment with DHA for 36 h
strongly inhibited cell death [35].
DHA killing of susceptible cell types, such as neurons [36],
may be explained by the stress caused by depletion of
NADPH and glutathione. But other cell types, such as astro-
cytes and osteoblasts, recycle DHA abundantly without
undergoing acute injury. The explanation for this discrepancy
may be that those cells that are most capable of producing
reducing equivalents are least susceptible to damage by DHA.
After intracellular DHA becomes reduced to AA, the latter
can function as a reductant. Each equivalent of AA in a cell
can reduce several equivalents of oxidants if the DHA thereby
produced can be recycled in the same cell, as has been dem-
onstrated for human erythrocytes [37]. The AA derived from
DHA also provides electrons to plasma membrane oxidore-
ductases and through them to extracellular oxidants [38]. Fur-
thermore, DHA uptake into cells may be followed by AA
e¥ux. For example, human erythrocytes [27] and HepG2 liver
cells [28] take up DHA, reduce it intracellularly and subse-
quently release AA to the extracellular £uid. This process
allows the reducing equivalents derived from cell metabolism
to be carried into the extracellular £uid and made available to
neighboring cells.
4. Diabetes
An excess of glucose during uncontrolled diabetes may im-
pair DHA uptake into cell types where DHA transport is
mediated largely by facilitative glucose transporters (Fig. 1).
Hormonal dysregulation may also contribute to local de¢cien-
cies in DHA recycling. Normally insulin increases the maxi-
mal rate of DHA transport by facilitative glucose transporters
in insulin-sensitive cells, thereby raising the intracellular AA
concentration [20]. A lack of insulin may impair DHA uptake
through facilitative glucose transporters during type I diabetes
(Fig. 1). Although insulin-like growth factor I can also acti-
vate insulin receptors to stimulate cellular uptake of DHA, it
has only one-tenth the potency of insulin [20]. Indeed, the
maximal rate of DHA uptake is decreased in lymphoblasts
from patients with type I diabetes and nephropathy [39].
Slowing of DHA uptake may lead to impaired regeneration
of AA and weakening of antioxidant defences in diabetes,
Fig. 1. Insulin stimulates accumulation of AA in osteoblasts ex-
posed to extracellular DHA. The DHA can enter cells through facil-
itative glucose transporters located in the plasma membrane and
then is reduced to AA, accumulating as the ascorbate ion (AA3).
Insulin acts through speci¢c receptor mechanisms to stimulate the
activity of facilitative glucose transporters in osteoblasts and other
insulin-sensitive cell types. During type I diabetes, a de¢ciency of in-
sulin and an excess of glucose may inhibit DHA uptake. This may
lead to a localized scarcity of AA3 in those osteoblasts that use vi-
tamin C for synthesizing collagen at sites of bone remodelling and
thereby contribute to osteopenia.
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especially in the presence of hyperglycemia. For instance, the
AA concentration is decreased and the DHA concentration is
increased in the sciatic nerve of rats made diabetic by strep-
tozotocin [40]. Furthermore, because intracellular AA is re-
quired for collagen synthesis by osteoblasts [29], de¢cient re-
cycling of DHA to AA in this cell type may contribute to the
development of osteopenia [20]. Support for this hypothesis
comes from the observation that feeding AA to diabetic preg-
nant rats improves skeletal development in their o¡spring [41].
Plasma and liver AA concentrations are signi¢cantly lower
in the Goto-Kakizaki diabetic rat than in controls [42].
NADPH-dependent regeneration of AA from DHA is also
suppressed in the liver of this diabetic rat [42]. Glucose-6-
phosphate dehydrogenase activity provides NADPH for
DHA reduction and a decrease in the activity of this enzyme
in diabetic rat liver may account for the subnormal AA con-
centrations [43].
5. In£ammation, sepsis and ischemia-reperfusion injury
Under pathological conditions characterized by oxidative
stress, AA is oxidized by reactive oxygen species at rates
that overwhelm the ability of cells to regenerate the vitamin.
For example, in£ammation in skin during wound healing
raises the extracellular concentration of DHA markedly [44].
Similarly, gastritis decreases the AA concentration and in-
creases the DHA concentration in the gastric juice of human
patients [45].
Redox cycling of vitamin C may also be abnormal during
the in£ammatory response to microbial infection, since the
rate of AA oxidation is increased in the serum of septic pa-
tients [46]. Moreover, ¢ndings with an in vitro model indicate
that septic conditions decrease recycling of DHA [25]. The
model consists of applying bacterial endotoxin (lipopolysac-
charide) and the in£ammatory cytokine interferon-Q (IFNQ) to
primary cultures of astrocytes. Lipopolysaccharide and IFNQ
induce nitric oxide synthase isoform 2, increase intracellular
levels of reactive oxygen species, and decrease the rate of
intracellular AA accumulation from extracellular AA or
DHA [25]. The oxidants produced during in£ammatory reac-
tions may directly alter the mechanisms by which cells recycle
DHA. For instance, prior exposure of astrocytes to peroxyl
radicals decreases their subsequent accumulation of intracel-
lular AA from extracellular DHA [23].
Ischemia-reperfusion injury in brain, caused by stroke or
trauma, also involves oxidative stress. Interventions that in-
crease cerebral AA concentration may be bene¢cial. Experi-
ments with transgenic mice lacking one of the most widely
distributed Naþ^ascorbate cotransporters (Slc23a1, an ortho-
log of the rat Svct2 and human hSvct2) indicate that this
transporter normally maintains the high AA concentration
found in brain [47]. However, because Naþ^ascorbate co-
transporters become downregulated when the intracellular
AA concentration is high [48], they may not be suitable tar-
gets for therapeutic strategies that attempt to raise intracellu-
lar AA to supraphysiological levels. Hence the suggestion that
DHA be injected as a pro-drug to increase the cerebral AA
concentration [49,50]. Radiotracer experiments have shown
that blood-borne DHA enters the brain and is converted to
AA [49]. Furthermore, intravenous injection of DHA has
been shown to improve the neurologic outcome in mice sub-
jected to experimental stroke, although no substantial increase
in cerebral AA concentration has been reported [50]. The
acute e¡ect of DHA in normal brain may be to inhibit behav-
ioral activation. Infusion of AA oxidase into rat brain con-
verts extracellular AA to DHA and leads to a rapid decline in
behavioral activation, with a 50^70% decrease in extracellular
AA concentration leading to a near-total inhibition of all
recorded behavior [51]. These putative actions of DHA are
reminiscent of those of general anesthetics, which also inhibit
behavioral activation acutely and confer neuroprotection
against cerebral ischemia [52].
Glutathione-dependent DHA reductase has been identi¢ed
by immunostaining in cerebral endothelial cells, neurons and
astrocytes [53]. DHA kills neurons in the absence of astrocytes
[36], whereas the latter cells are capable of regenerating AA
without ill e¡ect [21,23]. Brain cells produce cyclic AMP in
response to neurotransmitters and ischemia and this intracel-
lular messenger stimulates astrocytic uptake of DHA and ac-
cumulation of AA [21]. Astrocytes rapidly release the newly
formed AA when stimulated appropriately (Fig. 2). For in-
stance, swelling astrocytes with either glutamate or hypotonic
medium activates channels or pores in the plasma membrane,
through which large quantities of cytosolic AA di¡use to the
extracellular £uid [16,17]. Thus astrocytes detoxify the extra-
cellular £uid for neurons by clearing DHA and restoring AA.
6. Conclusions
DHA is ingested in the diet and also formed from oxidative
reactions in cells and extracellular £uid. However, vitamin C
oxidation is readily reversed by mechanisms that rapidly
transport DHA into metabolically competent cells and reduce
it there to AA. The resulting AA can be utilized in the same
cells or else released to the extracellular £uid. DHA recycling
Fig. 2. The DHA^AA shuttle between astrocytes and neurons. AA
(ionized as ascorbate, AA3) exits neurons by exocytosis and other
e¥ux mechanisms. The extracellular AA3 is taken up into adjacent
neurons through speci¢c Naþ^AA3 cotransporters located in the
plasma membrane. Additionally, AA3 becomes oxidized to DHA
and the latter di¡uses from the extracellular £uid into astrocytes
through Naþ-independent transporters. Intracellular DHA is con-
verted to AA3 by reductases, using reducing equivalents from gluta-
thione (GSH) or NADPH, and then returns to the extracellular £u-
id. Astrocyte swelling, such as that caused by glutamate, may
accelerate this DHA recycling process by activating plasma mem-
brane channels through which AA3 can di¡use from the astrocyte
cytosol to the extracellular £uid.
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mechanisms may decrease the amount of AA that humans
need to ingest. Pathological conditions that inhibit DHA re-
cycling may decrease AA concentrations and thereby impair
AA-dependent enzymatic and antioxidant activities.
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